141 Breast-conserving therapy (BCT) in stage I–II synchronous bilateral breast cancer (SBBC)

Author(s):  
Smitha V. Gollamudi ◽  
Rebecca S. Gelman ◽  
Gloria Peiro ◽  
Lindsey Schneider ◽  
James L. Connolly ◽  
...  
2021 ◽  
Vol 27 (3) ◽  
pp. 201-206
Author(s):  
Özlem Mermut ◽  
Aysun Ozsoy Ata ◽  
Didem Can Trabulus

Abstract Objective: We compared mono-isocenter and dual-isocenter plans in synchronous bilateral breast cancer (SBBC), which is defined as tumours occurring simultaneously in both breasts, and evaluated the effects of these differences in plans on organs-at-risk (OARs). Materials and methods: We evaluated 10 women with early stage, nod negative (Tis-2N0M0) SBBC. The treatment dose was determined to be 50 Gy. We used mean dose and VXGy to evaluate the OARs. To evaluate the effectiveness of treatment plans, Homogeneity index (HI), conformity index (CI) and sigma index (SI) and monitor units (MU) of monoisocenter (MIT) and dual-isocenter (DIT) plans were compared. During bilateral breast planning, for the single-centre plan, the isocenter was placed at the center of both breasts at a depth of 3-4 cm. For the two-center plan, dual-isocenters were placed on the right and left breasts. Results: No significant difference between the techniques in terms of the scope of the target volume was observed. Statistically significant results were not achieved in MIT and DIT plans for OARs. Upon comparing MIT and DIT, the right-side monitor unit (MU) value in DIT (p = 0.011) was statistically significantly lower than that in MIT. Upon comparing right-left side MIT and DIT, the MU value (p = 0.028) was significantly lower in DIT than MIT. Conclusion: SBBC irradiation is more complex than unilateral breast radiotherapy. No significant difference between both techniques and OARs was observed. However, we recommend MIT as a priority technique due to the ability to protect OARs, ease of administration during treatment, and the fact that the patient stays in the treatment unit for a shorter period of time.


2021 ◽  
pp. 72-73
Author(s):  
B Santhi ◽  
S Savitha ◽  
S Sujitha

Synchronous bilateral breast cancer is dened as two tumours diagnosed within 6 month interval and those above 6 months termed as metachronous breast cancer though there is difference in time interval specied by various clinicians. SBBC is a rare entity with incidence of 0.3 – 1.2% though it is recently increasing due to improved life expectancy after treatment and routine use of contralateral mammography. It is considered that synchronous breast tumours are independent tumours than to be secondary to metastatic spread from primary. Presence of indraductal component, different histology and different degree of differentiation implies that 2 they are independent tumors. Mostly women with BSBC are treated with aggressive measures as they are thought to be aggressive. Recently overall consensus is that bilateral breast cancer is amenable to breast conservation surgeries 1 without compromising surviva


2007 ◽  
Vol 33 (9) ◽  
pp. 1123-1123
Author(s):  
T IRVINE ◽  
D ALLEN ◽  
C GILLETT ◽  
I FENTIMAN ◽  
H HAMED

2018 ◽  
Vol 44 (6) ◽  
pp. 909
Author(s):  
Yan Yu Tan ◽  
Mihir Chandarana ◽  
Frank Liaw ◽  
Sadaf Jafferbhoy ◽  
Sekhar Marla ◽  
...  

1992 ◽  
Vol 10 (6) ◽  
pp. 976-983 ◽  
Author(s):  
A S Lichter ◽  
M E Lippman ◽  
D N Danforth ◽  
T d'Angelo ◽  
S M Steinberg ◽  
...  

PURPOSE Mastectomy versus excisional biopsy (lumpectomy) plus radiation for the treatment of stage I and II breast cancer was compared in a prospective randomized study. PATIENTS AND METHODS From 1979 to 1987, 247 women were randomized and 237 were treated on this study. All patients received a full axillary dissection and all node-positive patients received adjuvant chemotherapy with cyclophosphamide and doxorubicin. Radiation consisted of external-beam therapy to the whole breast with or without supraclavicular nodal irradiation followed by a boost to the tumor bed. RESULTS The minimum time on the study was 18 months and the median time on the study was 68 months. No differences in overall survival or disease-free survival were observed. Actuarial estimates at 5 years showed that 85% of mastectomy-treated patients were alive compared with 89% of the lumpectomy/radiation patients (P2 = .49; 95% two-sided confidence interval [CI] about this difference, 0% to 9% favoring lumpectomy plus radiation). The probability of failure in the irradiated breast was 12% by 5 years and 20% by 8 years according to actuarial estimates. Of 15 local breast failures, 14 were treated with and 12 were controlled by mastectomy; the ultimate local-regional control was similar in both arms of the trial. CONCLUSION These data add further weight to the conclusion that breast conservation using lumpectomy and breast irradiation is equivalent to mastectomy in terms of survival and ultimate local control for stage I and II breast cancer patients.


Sign in / Sign up

Export Citation Format

Share Document